78 Comparison of Positive Margin Rate of Breast Cancer in Higher BMI Patients

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 33-34

78 Comparison of Positive Margin Rate of Breast Cancer in Higher BMI Patients

78 Comparison of Positive Margin Rate of Breast Cancer in Higher BMI Patients

Background

There is about a 20% risk of positive margins in lumpectomy cases for breast cancer. For success to clear the cancer in question, a clear surgical margin must be taken. We hypothesized that those patients with higher BMIs may have more breast tissue, therefore allowing a larger specimen to be removed at the time of surgery, leading to a lower positive margin rate. We will also determine if those with a greater BMI will have more tissue removed from the specimen during their operation.

Materials and Methods

This was a retrospective chart review analysis of patients who underwent lumpectomy and re-excision of margins over 5 years. Patients who were included in our study were female, with estrogen receptor–positive/HER2-negative (ER+/HER2–) breast cancer. Patients were then divided based on body mass index (BMI) and characteristics of their tumor specimen investigated.

Results

A total of 1461 patients underwent lumpectomy between 2017 and 2022. Out of those patients, 81 met our criteria and underwent re-excision of margins. Additionally, 24 patients were found to have a BMI greater than 30. The average specimen diameter with those patients with a BMI greater than 30 was 6.54 cm compared with 4.95 cm in those with lower BMIs. In those patients where specimens were weighed, those patients with BMIs greater than 30, the average specimen was 48.17 g vs 16.95 g in patients with lower BMIs. Of note, 78 patients had re-excision of margins due to ductal carcinoma in situ, while 2 patients had re-excision for invasive ductal carcinoma and one patient for lobular carcinoma in situ.

Conclusion

Positive margins are a possible complication of lumpectomy, about a 20% risk, that can be mitigated by a larger amount of tissue. We show that patients who have a higher BMI allow more tissue to be taken and therefore lower risk of positive margin.

Articles in this issue

56 Paternal vs Maternal Inheritance of a BRCA Mutation: Is There a Difference in Presentation and Stage of Breast Cancer at Diagnosis?
56 Paternal vs Maternal Inheritance of a BRCA Mutation: Is There a Difference in Presentation and Stage of Breast Cancer at Diagnosis?
57 Tumor Morphology Concordance in Multifocal/Multicentric Triple- Negative and HER2+ Breast Cancers
57 Tumor Morphology Concordance in Multifocal/Multicentric Triple- Negative and HER2+ Breast Cancers
59 Are Choosing Wisely Guidelines Applicable to Patients With a High Ki-67 Proliferation Index and Magee Equation Score?
59 Are Choosing Wisely Guidelines Applicable to Patients With a High Ki-67 Proliferation Index and Magee Equation Score?
60 Nipple-Sparing Mastectomy in Patients With BRCA and Other Breast Cancer–Related Gene Mutations
60 Nipple-Sparing Mastectomy in Patients With BRCA and Other Breast Cancer–Related Gene Mutations
61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?
61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?
63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q
63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q
64 A Prospective Study to Accurately Define the Nipple-Ward Margins in Patients Undergoing Lumpectomy for Breast Cancer
64 A Prospective Study to Accurately Define the Nipple-Ward Margins in Patients Undergoing Lumpectomy for Breast Cancer
65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population
65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population
67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery
67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery
68 Upper Extremity Disability Assessment Following Breast Cancer Surgery Using QuickDASH in an Ethnic Minority Population
68 Upper Extremity Disability Assessment Following Breast Cancer Surgery Using QuickDASH in an Ethnic Minority Population
70 Malignancy Upgrade Rates of Discordant Breast Lesions
70 Malignancy Upgrade Rates of Discordant Breast Lesions
71 Beyond the Surface: Suspicious Nipple Lesions
71 Beyond the Surface: Suspicious Nipple Lesions
72 Breast Cancer After Breast Augmentation: A Multicenter Collaborative Study Of Patient Management and Outcomes
72 Breast Cancer After Breast Augmentation: A Multicenter Collaborative Study Of Patient Management and Outcomes
73 Short- and Long-Term Outcomes in Use of Titanium-Coated Polypropylene Meshes in Immediate Breast Reconstruction: A Cost-Effective and Safe Option?
73 Short- and Long-Term Outcomes in Use of Titanium-Coated Polypropylene Meshes in Immediate Breast Reconstruction: A Cost-Effective and Safe Option?
74 Lessons Learned From a Breast Surgery ERAS Program in an Oncologic Ambulatory Center
74 Lessons Learned From a Breast Surgery ERAS Program in an Oncologic Ambulatory Center

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Related Content
OSZAR »